Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Neurotransmitter Imbalance in the Brain and Alzheimer’s Disease Pathology

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Causes of Death in People with Dementia from 2002 to 2015: A Nationwide Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Comparing a Single Clinician Versus a Multidisciplinary Consensus Conference Approach for Dementia Diagnostics

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Is the Frontal Lobe the Primary Target of SARS-CoV-2?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Changes in the lipidome in type 1 diabetes following low carbohydrate diet: Post-hoc analysis of a randomized crossover trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Stuart G Snowden
  • Amera Ebshiana
  • Abdul Hye
  • Olga Pletnikova
  • Richard O'Brien
  • Yang An
  • Juan C. Troncoso
  • Cristina Legido-Quigley
  • Madhav Thambisetty
Vis graf over relationer
BACKGROUND: Cholinesterase inhibitors represent three of the four treatments for Alzheimer's disease (AD), and target the pathological reduction of acetylcholine levels. Here we aimed to study the role of other neurotransmitter pathways in AD pathology.

OBJECTIVE: This study aimed to determine associations between AD pathology at both symptomatic and asymptomatic stages of disease progression, and the metabolism of a range of non-cholinergic neurotransmitters.

METHODS: Tissue samples were obtained from three groups, controls, AD, and 'asymptomatic AD' (ASYMAD), i.e., cognitively normal individuals that had significant AD neuropathology. Three brain areas were studied, the middle frontal gyrus (MFG), the inferior temporal gyrus (ITG), and the cerebellum.

RESULTS: 12 of 15 metabolites involved in neurotransmitter metabolism were shown to be associated with AD pathology. Decreases in dopamine were most pronounced in the MFG with lower levels seen in the ASYMAD group compared to control (FC = 0.78, p = 2.9×10-2). In the ITG significant changes were seen in GABAergic and serotonin metabolism between control and AD patients; however, these changes were not seen between control and ASYMAD individuals.

CONCLUSION: These results indicate that dopamine could be depleted in brains with AD pathology but intact cognition, while an imbalance of several neurotransmitters is evident in the brains of AD patients.
OriginalsprogEngelsk
TidsskriftJournal of Alzheimer's Disease
Vol/bind72
Udgave nummer1
Sider (fra-til)35-43
Antal sider8
ISSN1387-2877
StatusUdgivet - 29 okt. 2019
Eksternt udgivetJa

ID: 58576713